FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4281640392> ?p ?o ?g. }

• W4281640392 endingPage "TPS1125" @default.
• W4281640392 startingPage "TPS1125" @default.
• W4281640392 abstract "TPS1125 Background: Triple-negative breast cancer (TNBC) is the subtype of breast cancer with the worst prognosis and is the subtype most often associated with germline mutations of BRCA1 and certain other genes. Alpha-lactalbumin (aLA) is a milk protein that is expressed in lactating breasts but not at other times or in other normal tissues. Expression of aLA is found in approximately 70% of TNBC (Cancers PMID: 27322324) so is an attractive immunologic target for TNBC based on the “retired protein hypothesis” (Semin Immunol PMID: 31926646). Pre-clinical studies have shown that vaccination with aLA provides treatment of established and, more potently, protection from development of autochthonous tumors in transgenic murine models of breast cancer and against 4T1 transplantable breast cancer in BALB/c mice (Nat Med PMID: 20512124). We are conducting a Phase I trial in patients with early stage TNBC to demonstrate the safety of this approach and to document the ability to produce a meaningful immunologic response to aLA. Methods: Patients with ER-negative, PR-negative, HER2-negative breast cancer of pathologic stage I-III or who had residual disease after standard pre-operative systemic therapy are being entered into a Phase I trial of alpha-lactalbumin with a GMP-grade zymosan adjuvant in Montanide ISA 51 VG vehicle. Participants must be within 3 years of initiation of treatment and have no evidence of recurrence. Patients receive a total of 3 vaccinations administered once every 2 weeks with doses escalated using a 3+3 trial design. Toxic events of Common Terminology Criteria for Adverse Events (CTCAE) grade 2 or greater are considered dose-limiting. Dose levels being tested are alpha-lactalbumin/zymosan 0.01 mg/0.01 mg, 0.1 mg/0.1 mg, and 1 mg/1 mg. Patients are being monitored for toxicity until 84 days after the first vaccination or resolution of toxicity, whichever is later. Blood is being drawn prior to therapy and 14, 28, and 56 days after the first vaccination to assess cellular response using enzyme-linked immunosorbent spot (ELISpot) assays of interferon-gamma and interleukin-17 production in response to aLA. Humoral response to aLA vaccination is being assessed by enzyme-linked immunosorbent assay (ELISA). After identification of the Maximum Tolerated Dose we will expand the dose levels associated with effective tumor immunity and enroll a cohort of patients without cancer planning to undergo prophylactic bilateral mastectomy. Funding Source: Department of Defense (W81XWH-17-1-0592 and W81XWH-17-1-0593). Clinical trial information: NCT04674306." @default.
• W4281640392 created "2022-06-13" @default.
• W4281640392 creator A5004756333 @default.
• W4281640392 creator A5020430806 @default.
• W4281640392 creator A5030476275 @default.
• W4281640392 creator A5034645538 @default.
• W4281640392 creator A5044282307 @default.
• W4281640392 creator A5060860226 @default.
• W4281640392 creator A5071015335 @default.
• W4281640392 creator A5083301757 @default.
• W4281640392 creator A5087616048 @default.
• W4281640392 creator A5088914288 @default.
• W4281640392 date "2022-06-01" @default.
• W4281640392 modified "2023-09-26" @default.
• W4281640392 title "Phase I trial of an alpha-lactalbumin vaccine in patients with moderate- to high-risk operable triple-negative breast cancer (TNBC)." @default.
• W4281640392 doi "https://doi.org/10.1200/jco.2022.40.16_suppl.tps1125" @default.
• W4281640392 hasPublicationYear "2022" @default.
• W4281640392 type Work @default.
• W4281640392 citedByCount "2" @default.
• W4281640392 countsByYear W42816403922022 @default.
• W4281640392 countsByYear W42816403922023 @default.
• W4281640392 crossrefType "journal-article" @default.
• W4281640392 hasAuthorship W4281640392A5004756333 @default.
• W4281640392 hasAuthorship W4281640392A5020430806 @default.
• W4281640392 hasAuthorship W4281640392A5030476275 @default.
• W4281640392 hasAuthorship W4281640392A5034645538 @default.
• W4281640392 hasAuthorship W4281640392A5044282307 @default.
• W4281640392 hasAuthorship W4281640392A5060860226 @default.
• W4281640392 hasAuthorship W4281640392A5071015335 @default.
• W4281640392 hasAuthorship W4281640392A5083301757 @default.
• W4281640392 hasAuthorship W4281640392A5087616048 @default.
• W4281640392 hasAuthorship W4281640392A5088914288 @default.
• W4281640392 hasConcept C121608353 @default.
• W4281640392 hasConcept C126322002 @default.
• W4281640392 hasConcept C143998085 @default.
• W4281640392 hasConcept C203014093 @default.
• W4281640392 hasConcept C2777863537 @default.
• W4281640392 hasConcept C2780110267 @default.
• W4281640392 hasConcept C530470458 @default.
• W4281640392 hasConcept C535046627 @default.
• W4281640392 hasConcept C71924100 @default.
• W4281640392 hasConceptScore W4281640392C121608353 @default.
• W4281640392 hasConceptScore W4281640392C126322002 @default.
• W4281640392 hasConceptScore W4281640392C143998085 @default.
• W4281640392 hasConceptScore W4281640392C203014093 @default.
• W4281640392 hasConceptScore W4281640392C2777863537 @default.
• W4281640392 hasConceptScore W4281640392C2780110267 @default.
• W4281640392 hasConceptScore W4281640392C530470458 @default.
• W4281640392 hasConceptScore W4281640392C535046627 @default.
• W4281640392 hasConceptScore W4281640392C71924100 @default.
• W4281640392 hasFunder F4320306078 @default.
• W4281640392 hasIssue "16_suppl" @default.
• W4281640392 hasLocation W42816403921 @default.
• W4281640392 hasOpenAccess W4281640392 @default.
• W4281640392 hasPrimaryLocation W42816403921 @default.
• W4281640392 hasRelatedWork W1966181922 @default.
• W4281640392 hasRelatedWork W1999292713 @default.
• W4281640392 hasRelatedWork W2050936961 @default.
• W4281640392 hasRelatedWork W2101673433 @default.
• W4281640392 hasRelatedWork W2163676795 @default.
• W4281640392 hasRelatedWork W2366029130 @default.
• W4281640392 hasRelatedWork W2376078656 @default.
• W4281640392 hasRelatedWork W2554176272 @default.
• W4281640392 hasRelatedWork W3005028195 @default.
• W4281640392 hasRelatedWork W80971072 @default.
• W4281640392 hasVolume "40" @default.
• W4281640392 isParatext "false" @default.
• W4281640392 isRetracted "false" @default.
• W4281640392 workType "article" @default.